Skip to main content

Table 1 Characteristics of patients according to pharmacy channel where index oral oncolytic prescription was filleda

From: Impact of pharmacy channel on adherence to oral oncolytics

Characteristicb Specialty Traditional Retail P-value
Number of Patients 11,972 30,394  
 Row Percent 28.3% 71.7%  
Mean (SD) Age 63.9 (12.5) 64.4 (12.9) <0.001
Age Group, N (%): <0.001
 18–34 years 178 1.5% 493 1.6%  
 35–44 years 620 5.2% 1616 5.3%  
 45–54 years 1895 15.8% 4710 15.5%  
 55–64 years 3452 28.8% 8239 27.1%  
 65–74 years 3032 25.3% 7662 25.2%  
 75–84 years 2625 21.9% 6734 22.2%  
 85+ years 170 1.4% 940 3.1%  
Male, N (%): 5416 45.2% 13,068 43.0% <0.001
Region, N (%): <0.001
 Northeast 3531 29.5% 6439 21.2%  
 Midwest 2054 17.2% 6217 20.5%  
 South 4173 34.9% 10,960 36.1%  
 West 1813 15.1% 5107 16.8%  
 Unknown 401 3.3% 1671 5.5%  
Index Study Year, N (%) <0.001
 2007 1118 9.3% 2670 8.8%  
 2008 2118 17.7% 5880 19.4%  
 2009 2860 23.9% 8176 26.9%  
 2010 3451 28.8% 8240 27.1%  
 2011 2425 20.3% 5428 17.9%  
Index Oncolytic Received, N (%) <0.001
 Erlotinib 4774 39.9% 10,297 33.9%  
 Capecitabine 4906 41.0% 15,156 49.9%  
 Imatinib 2292 19.1% 4941 16.3%  
Copayc Amount Categorized <0.001
 $0–49 7112 59.4% 16,921 55.7%  
 $50–100 1572 13.1% 4127 13.6%  
 $101–150 761 6.4% 1877 6.2%  
 $151–200 350 2.9% 920 3.0%  
 $201–250 257 2.2% 656 2.2%  
 $251–350 199 1.7% 651 2.1%  
 $351–500 268 2.2% 900 3.0%  
 $501–1000 694 5.8% 2137 7.0%  
  > $1000 759 6.3% 2205 7.3%  
Mean (SD) Copayc Amount (per 30 days) 220.7 (548.2) 256.1 (595.31) <0.001
 P25 16.4 15.0  
 Median 36.0 40.0  
 P75 111.4 142.86  
Mean (SD) Days Supplied Per Prescription 33.7 (20.7) 25.0 (12.5) <0.001
 Median 30.0 26.4  
  1. Note: Study index date refers to the first date that a patient attempted to fill the index oral oncolytic prescription.
  2. Abbreviations: SD, standard deviation; N, number of patients; P25, 25th percentile; P75, 75th percentile
  3. aPharmacy channel defined based on the channel where patient filled their initial (index) oral oncolytic
  4. bGroup comparisons were made using 2-sided Pearson chi-square for categorical measures, t-test statistic for mean age and Wilcoxon test for mean copay, P-values are presented for comparisons using traditional retail as reference group
  5. cMean copay amount (per 30 day supply) calculated using patients’ prescription drug claims for index oral oncolytic from study index until end of follow-up and inflated to 2011 US dollars